ArticleOpen biology2018
Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle.
Article in Open biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Molecular Boolean analyses of chemokine (C-C motif) receptor 1, αBiochemistry and biophysics reports · 2026Article
- Activation of Chemokine (C-C Motif) Receptor 1 Modulates αJournal of the American Heart Association · 2025Article
- Chemokine receptor hetero-oligomers regulate monocyte chemotaxis.Life science alliance · 2024Article
- G protein activation via chemokine (C-X-C motif) receptor 4 and αFEBS letters · 2023Article
- αPharmacological research · 2023Article
- Heteromerization between αFEBS letters · 2022Article
- αProceedings of the National Academy of Sciences of the United States of America · 2022Article
- The Chemokine (C-C Motif) Receptor 2 Antagonist INCB3284 Reduces Fluid Requirements and Protects From Hemodynamic Decompensation During Resuscitation From Hemorrhagic Shock.Critical care explorations · 2022Article
- Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Class A G protein-coupled receptors assemble into functional higher-order hetero-oligomers.FEBS letters · 2021Article
- Chemokine receptor antagonists with αJournal of basic and clinical physiology and pharmacology · 2021Article
- Detection of genome-edited and endogenously expressed G protein-coupled receptors.The FEBS journal · 2021Review
- Plasticity of seven-transmembrane-helix receptor heteromers in human vascular smooth muscle cells.PloS one · 2021Article
- Regulation of the thrombin/protease-activated receptor 1 axis by chemokine (CThe Journal of biological chemistry · 2020Article
- Dual-Color Single-Cell Imaging of the Suprachiasmatic Nucleus Reveals a Circadian Role in Network Synchrony.Neuron · 2020Article
- Characterization of heteromeric complexes between chemokine (C-X-C motif) receptor 4 and αBiochemical and biophysical research communications · 2020Article
- Natural and engineered chemokine (C-X-C motif) receptor 4 agonists prevent acute respiratory distress syndrome after lung ischemia-reperfusion injury and hemorrhage.Scientific reports · 2020Article
- Arrestin recruitment and signaling by G protein-coupled receptor heteromers.Neuropharmacology · 2019Review
- Effects of ethanol and ethanol metabolites on intrinsic function of mesenteric resistance arteries.PloS one · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Recent observations suggest that atypical chemokine receptor (ACKR)3 and chemokine (C-X-C motif) receptor (CXCR)4 regulate human vascular smooth muscle function through hetero-oligomerization with α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.